Printer Friendly

MACDONALD NAMED PRESIDENT OF ICN BIOMEDICALS

 COSTA MESA, Calif., March 24 /PRNewswire/ -- Bill A. MacDonald, 45, has been elected president of ICN Biomedicals Inc. (AMEX: BIM), a worldwide supplier of biotechnology research products and medical diagnostics.
 MacDonald previously served as executive vice president, tax and corporate development for ICN Pharmaceuticals, ICN Biomedicals' parent company.
 MacDonald joined ICN Pharmaceuticals in March 1982. Prior to joining ICN, he was an executive with Pertec Computer Corp. and Republic Corp. in California.
 MacDonald will report to Milan Panic, chairman and chief executive officer of ICN Biomedicals. Richard M. Fallis remains chief operating officer.
 ICN Biomedicals produces, markets and distributes more than 55,000 products to the biomedical research community in 130 countries. Its products include biochemicals, organic chemicals, radiochemicals, cell biology products, immunobiologicals and diagnostics. Very few biomedical laboratory research experiments occur in which at least one of the company's 55,000 products does not play a role.
 -0- 3/24/93
 /CONTACT: Paul Knopick of ICN Biomedicals, 714-545-0100, ext. 2465/
 (BIM)


CO: ICN Biomedicals Inc.; ICN Pharmaceuticals ST: California IN: MTC SU: PER

JL-LS -- LA005 -- 8974 03/24/93 09:01 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 24, 1993
Words:183
Previous Article:THE ROCKETTES KICK UP THEIR HEELS WITH THE WORLD'S MOST POPULAR DOLL; BARBIE BECOMES PART OF THE LEGENDARY DANCE TROUPE
Next Article:ENVIROMINT IN AGREEMENT WITH INTERNATIONAL INSURANCE INDUSTRIES INC. PROPOSES TO ACQUIRE THE HOME-STAKE COMPANIES
Topics:


Related Articles
ICN BIOMEDICALS INC. DECLARES QUARTERLY DIVIDEND
ALPHA 1 BIOMEDICALS APPOINTS HAUTALA TO VICE PRESIDENT, CORPORATE DEVELOPMENT
ICN BIOMEDICALS INC. ANNOUNCES RESTRUCTURING
ICN BIOMEDICALS INC. INCREASES QUARTERLY DIVIDEND 13 PERCENT
ICN BIOMEDICALS REPORTS THIRD QUARTER RESULTS
ICN BIOMEDICALS INC. ANNOUNCES FOURTH QUARTER DIVIDEND
ICN BIOMEDICALS REPORTS WRITE-OFFS
ICN BIOMEDICALS INC. ANNOUNCES THIRD QUARTER DIVIDEND
ICN BIOMEDICALS INC. REPORTS THIRD QUARTER RESULTS
ZAXIS ANNOUNCES AGREEMENT WITH ICN PHARMACEUTICALS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters